Biotech Spotlight
-
Stock via Getty Images
Biotech SpotlightCRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
By Kelly Bilodeau • Feb. 18, 2025 -
Permission granted by Fractyl Health
Q&A // Biotech SpotlightBeyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.
By Amy Baxter • Feb. 10, 2025 -
Permission granted by Candel Therapeutics
Q&A // Biotech SpotlightAfter layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
By Michael Gibney • Jan. 9, 2025 -
iStock via Getty Images
Q&A // Biotech SpotlightAn RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
By Michael Gibney • Nov. 26, 2024 -
Getty Images via Getty Images
Q&A // Biotech SpotlightA biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
By Michael Gibney • Aug. 13, 2024 -
Permission granted by Arialys Therapeutics
Biotech SpotlightA biotech dousing ‘fires’ in the brain that plagued a bestselling author
Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.
By Alexandra Pecci • Aug. 7, 2024 -
Doucefleur via Getty Images
Biotech SpotlightA new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.
By Alexandra Pecci • July 17, 2024 -
Stock via Getty Images
Biotech SpotlightMining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.
By Meagan Parrish • July 15, 2024 -
Permission granted by Prologue Medicines
Biotech SpotlightProtein power: a biotech mining viruses to fight disease
Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.
By Kelly Bilodeau • July 1, 2024 -
Permission granted by FibroBiologics
Biotech SpotlightRegenerative cell therapy biotech uses IPO to blast into human trials
Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.
By Amy Baxter • June 5, 2024 -
Stock via Getty Images
Biotech SpotlightMythic Therapeutics aims to overcome one of ADC’s long-standing challenges
By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.
By Alexandra Pecci • May 30, 2024 -
Permission granted by Ocugen
Biotech SpotlightTraditional gene therapies are uber-niche. Ocugen hopes to change that.
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
By Alexandra Pecci • April 15, 2024 -
Stock via Getty Images
Biotech SpotlightWhat’s old is new: The revival of a one-time radiotherapy cancer treatment
TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.
By Amy Baxter • April 10, 2024 -
Stock via Getty Images
Q&A // Biotech SpotlightGSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
By Alexandra Pecci • March 19, 2024 -
Stock via Getty Images
Biotech SpotlightBlack Diamond looks to outwit cancer mutations
Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.
By Kelly Bilodeau • March 4, 2024 -
Permission granted by Mural Oncology
Q&AWhy a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
By Alexandra Pecci • Feb. 6, 2024 -
Permission granted by 4DMT
Q&A // Biotech SpotlightOne biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.
By Michael Gibney • Jan. 10, 2024 -
iStock via Getty Images
Q&A // Biotech SpotlightThis biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain
Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.
By Michael Gibney • Dec. 19, 2023 -
Permission granted by Talus Bio
Biotech SpotlightA biotech tackles drug discovery with transcription factor know-how
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
By Michael Gibney • Nov. 15, 2023 -
Permission granted by Avidity
Biotech SpotlightA new delivery method muscling its way into the RNA space
With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.
By Kelly Bilodeau • Nov. 8, 2023 -
Stock via Getty Images
Biotech SpotlightCidara’s J&J-partnered immunotherapy could target flu and cancer
On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.
By Alexandra Pecci • Oct. 26, 2023 -
Getty Images via Getty Images
Biotech SpotlightAn ‘inverse vaccine’ takes aim at autoimmune diseases
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
By Kelly Bilodeau • Oct. 23, 2023 -
Stock via Getty Images
Q&A // Biotech SpotlightTo close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
By Alexandra Pecci • Oct. 11, 2023 -
Stock via Getty Images
Biotech SpotlightA biotech ‘tuning’ the genome for a potentially safer gene therapy
Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.
By Kelly Bilodeau • Oct. 9, 2023 -
Stock via Getty Images
Biotech SpotlightImmuneering takes aim at cancer’s ‘superhighway’
After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.
By Kelly Bilodeau • Sept. 11, 2023
